Supernus Pharmaceuticals (NASDAQ: SUPN)
Supernus Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Supernus Pharmaceuticals Company Info
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
News & Analysis
Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy
Supernus Pharmaceuticals' revenue mix is shifting, and it could soon have more sales on the way.
Why Supernus' Acquisition of Adamas Is a Smart Move
Adamas looks like a good fit for Supernus.
Why Supernus Pharmaceuticals Stock Is Soaring Today
The biopharmaceutical company released a regulatory update.
These 2 Scrappy Biotechs Could Skyrocket in April
They've both taken a beating, but their fortunes may soon change.
3 Healthcare Stocks That Could Be Millionaire-Makers
With solid revenue growth, these stocks have the potential to more than triple over the next few years.
3 Undervalued Biotechs Worth Adding to Your Watch List
Their recent struggles may soon give way to rising market interest and more lucrative returns.
Why Supernus Pharmaceuticals Stock Is Rising Today
The company announced positive results from a clinical trial.
3 Small-Cap Stocks With Big-Cap Potential
These stocks are just temporarily inconvenienced large caps in the making.
Valuation
Earnings Transcripts
Supernus Pharmaceuticals, inc (SUPN) Q3 2021 Earnings Call Transcript
SUPN earnings call for the period ending September 30, 2021.
Supernus Pharmaceuticals, inc (SUPN) Q2 2021 Earnings Call Transcript
SUPN earnings call for the period ending June 30, 2021.
Supernus Pharmaceuticals Inc (SUPN) Q1 2021 Earnings Call Transcript
SUPN earnings call for the period ending March 31, 2021.
Supernus Pharmaceuticals Inc (SUPN) Q4 2020 Earnings Call Transcript
SUPN earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.